{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:11:47Z","timestamp":1789506707345,"version":"build-2803163510"},"reference-count":114,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P36105-B"],"award-info":[{"award-number":["P36105-B"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.drudis.2026.104724","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:59:32Z","timestamp":1781798372000},"page":"104724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Critical evaluation of the key mediators causing life-threatening symptoms during human anaphylaxis"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8294-0797","authenticated-orcid":false,"given":"Thomas","family":"Boehm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104724_b0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11882-011-0231-6","article-title":"Mediators released during human anaphylaxis","volume":"12","author":"Stone","year":"2012","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.drudis.2026.104724_b0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jaci.2017.06.012","article-title":"Diagnosis and management of anaphylaxis in precision medicine","volume":"140","author":"Castells","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0015","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2017.06.003","article-title":"The pathophysiology of anaphylaxis","volume":"140","author":"Reber","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0020","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jaci.2021.03.043","article-title":"Metabolome and lipidome derangements during a severe mast cell activation event in a patient with indolent systemic mastocytosis","volume":"148","author":"Boehm","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0025","first-page":"44","article-title":"Intraepithelial migration of nasal mucosal mast cells in hay fever","volume":"80","author":"Enerbaeck","year":"1986","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0030","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/art.1780270803","article-title":"Quantitation of human synovial mast cells in rheumatoid arthritis and other rheumatic diseases","volume":"27","author":"Godfrey","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2026.104724_b0035","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1164\/ajrccm\/148.1.80","article-title":"Intraepithelial mast cells in allergic and nonallergic asthma. Assessment using bronchial brushings","volume":"148","author":"Gibson","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.drudis.2026.104724_b0040","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.bja.2020.08.024","article-title":"Epidemiology and outcome of patients admitted to intensive care after anaphylaxis in France: a retrospective multicentre study","volume":"125","author":"Guerci","year":"2020","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.drudis.2026.104724_b0045","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jaci.2022.04.023","article-title":"Massive release of TH2 cytokines induced a cytokine storm during a severe mast cell activation event in a patient with indolent systemic mastocytosis","volume":"150","author":"Boehm","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0050","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00011-025-02032-5","article-title":"COVID-19 mRNA-1273 vaccination induced mast cell activation with strongly elevated Th2 cytokines in a systemic mastocytosis patient","volume":"74","author":"Weiss-Tessbach","year":"2025","journal-title":"Inflamm Res"},{"key":"10.1016\/j.drudis.2026.104724_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104349","article-title":"Are leukotrienes really the world\u2019s best bronchoconstrictors and at least 100 to 1000 times more potent than histamine?","volume":"30","author":"Boehm","year":"2025","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104724_b0060","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0091-6749(06)80017-5","article-title":"Insect-sting challenge in 138 patients: relation between clinical severity of anaphylaxis and mast cell activation","volume":"90","author":"Van der Linden","year":"1992","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0065","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2222.1976.tb01934.x","article-title":"Oral aspirin challenges in asthmatic patients: a study of plasma histamine","volume":"6","author":"Stevenson","year":"1976","journal-title":"Clin Allergy"},{"key":"10.1016\/j.drudis.2026.104724_b0070","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaci.2015.06.021","article-title":"Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug-related urticaria and angioedema","volume":"136","author":"Kowalski","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0075","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1016\/j.jaip.2020.07.043","article-title":"Chronic urticaria with NSAID-exacerbated cutaneous disease: a (NSAID) challenge worth taking","volume":"8","author":"Cook","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.drudis.2026.104724_b0080","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1164\/ajrccm\/148.1.87","article-title":"Effect of inhaled prostaglandin E2 on allergen-induced asthma","volume":"148","author":"Pavord","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.drudis.2026.104724_b0085","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1164\/ajrccm.153.2.8564100","article-title":"Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma","volume":"153","author":"Sestini","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.drudis.2026.104724_b0090","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.jaci.2015.04.002","article-title":"Prostaglandin E2 inhibits mast cell-dependent bronchoconstriction in human small airways through the E prostanoid subtype 2 receptor","volume":"136","author":"Saefholm","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0095","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jaci.2017.02.030","article-title":"Mast cell-derived prostaglandin D2 attenuates anaphylactic reactions in mice","volume":"140","author":"Nakamura","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0100","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.jaci.2020.03.046","article-title":"PGE2 deficiency predisposes to anaphylaxis by causing mast cell hyperresponsiveness","volume":"146","author":"Rastogi","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174282","article-title":"Prostaglandin D2 inhibits mediator release and antigen induced bronchoconstriction in the Guinea pig trachea by activation of DP1 receptors","volume":"907","author":"S\u00e4fholm","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2026.104724_b0110","first-page":"422","article-title":"Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues","volume":"46","author":"Humphrey","year":"1982","journal-title":"Lab Invest"},{"key":"10.1016\/j.drudis.2026.104724_b0115","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0162-3109(84)90017-1","article-title":"Effect of platelet activating factor on endothelial permeability to plasma macromolecules","volume":"8","author":"Handley","year":"1984","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.drudis.2026.104724_b0120","first-page":"617","article-title":"Characterization of cutaneous vascular permeability induced by platelet-activating factor in Guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist","volume":"52","author":"Hwang","year":"1985","journal-title":"Lab Invest"},{"key":"10.1016\/j.drudis.2026.104724_b0125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00915417","article-title":"Permeability-increasing ability of PAF-acether in rat skin","volume":"9","author":"Gerdin","year":"1985","journal-title":"Inflammation"},{"key":"10.1016\/j.drudis.2026.104724_b0130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2125.1991.tb05617.x","article-title":"The role of histamine in the acute inflammatory responses to intradermal platelet activating factor","volume":"32","author":"Sciberras","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104724_b0135","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0091-6749(88)91005-6","article-title":"Effect of a PAF antagonist, BN52063, on antigen-induced, acute, and late-onset cutaneous responses in atopic subjects","volume":"82","author":"Roberts","year":"1988","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0140","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2222.1991.tb01690.x","article-title":"Effect of azelastine and ketotifen on the bronchial and skin responses to platelet-activating factor in humans","volume":"21","author":"Lai","year":"1991","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.drudis.2026.104724_b0145","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF01999625","article-title":"Actions of disodium cromoglycate (DSCG) on human skin responses to histamine, codeine and PAF-acether","volume":"16","author":"Archer","year":"1985","journal-title":"Agents Actions"},{"key":"10.1016\/j.drudis.2026.104724_b0150","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/0091-6749(88)90890-1","article-title":"Ketotifen inhibits the cutaneous but not the airway responses to platelet-activating factor in man","volume":"81","author":"Chung","year":"1988","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0155","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2340\/0001555565409412","article-title":"Experimental pruritus evoked by platelet activating factor (PAF-acether) in human skin","volume":"65","author":"Fjellner","year":"1985","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.drudis.2026.104724_b0160","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2230.1996.tb00008.x","article-title":"Effects of H1- and H2-antihistamines on platelet-activating factor and bradykinin-induced inflammatory responses in human skin","volume":"21","author":"Sansom","year":"1996","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.drudis.2026.104724_b0165","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1042\/bj2710501","article-title":"Biosynthesis of PAF-acether. Activators of protein kinase C stimulate cultured mast cell acetyltransferase without stimulating PAF-acether synthesis","volume":"271","author":"Joly","year":"1990","journal-title":"Biochem J"},{"key":"10.1016\/j.drudis.2026.104724_b0170","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/j.1432-1033.1993.tb18205.x","article-title":"Biosynthesis of platelet-activating factor in cultured mast cells. Involvement of the CoA-independent transacylase demonstrated by analysis of the molecular species of platelet-activating factor","volume":"216","author":"Colard","year":"1993","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.drudis.2026.104724_b0175","first-page":"614","article-title":"Characterization of inflammatory mediator release from purified human lung mast cells","volume":"133","author":"Schleimer","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.drudis.2026.104724_b0180","first-page":"500","article-title":"Characterization of platelet-activating factor synthesized by normal and granulocyte-macrophage colony-stimulating factor-primed human eosinophils","volume":"77","author":"Triggiani","year":"1992","journal-title":"Immunology"},{"key":"10.1016\/j.drudis.2026.104724_b0185","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/0091-6749(90)90217-R","article-title":"Comparison of the generation of platelet-activating factor and leukotriene C4 in human eosinophils stimulated by unopsonized zymosan and by the calcium ionophore A23187: the effects of nedocromil sodium","volume":"85","author":"Burke","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0190","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0090-6980(92)90061-W","article-title":"Relative amounts of 1-O-alkyl- and 1-acyl-2-acetyl-sn-glycero-3-phosphocholine in stimulated endothelial cells","volume":"43","author":"Whatley","year":"1992","journal-title":"Prostaglandins"},{"key":"10.1016\/j.drudis.2026.104724_b0195","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1073\/pnas.81.11.3534","article-title":"Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin","volume":"81","author":"Prescott","year":"1984","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104724_b0200","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/37622","article-title":"Role of cytosolic phospholipase A2 in allergic response and parturition","volume":"390","author":"Uozumi","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104724_b0205","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF01978737","article-title":"Release of platelet-activating factor (PAF-acether) and arachidonic acid metabolites from alveolar macrophages","volume":"11","author":"Arnoux","year":"1981","journal-title":"Agents Actions"},{"key":"10.1016\/j.drudis.2026.104724_b0210","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/BF01965089","article-title":"Release of PAF-acether from human blood monocytes","volume":"12","author":"Arnoux","year":"1982","journal-title":"Agents Actions"},{"key":"10.1016\/j.drudis.2026.104724_b0215","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1046\/j.1365-2222.2003.01726.x","article-title":"Regulation and kinetics of platelet-activating factor and leukotriene C4 synthesis by activated human basophils","volume":"33","author":"Lie","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.drudis.2026.104724_b0220","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1172\/JCI111957","article-title":"Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate","volume":"76","author":"McIntyre","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2026.104724_b0225","doi-asserted-by":"crossref","first-page":"660","DOI":"10.4049\/jimmunol.147.2.660","article-title":"Differential synthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine and platelet-activating factor by human inflammatory cells","volume":"147","author":"Triggiani","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0230","doi-asserted-by":"crossref","first-page":"9355","DOI":"10.1016\/S0021-9258(19)83523-8","article-title":"Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators)","volume":"254","author":"Demopoulos","year":"1979","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104724_b0235","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa070030","article-title":"Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis","volume":"358","author":"Vadas","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104724_b0240","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jaci.2012.08.016","article-title":"Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis","volume":"131","author":"Vadas","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0245","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1111\/all.15308","article-title":"Platelet-activating factor acetylhydrolase is a biomarker of severe anaphylaxis in children","volume":"77","author":"Upton","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.drudis.2026.104724_b0250","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.4049\/jimmunol.1600614","article-title":"Mast cell degranulation is accompanied by the release of a selective subset of extracellular vesicles that contain mast cell-specific proteases","volume":"197","author":"Groot Kormelink","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0255","doi-asserted-by":"crossref","first-page":"E10692","DOI":"10.1073\/pnas.1809938115","article-title":"Mastocytosis-derived extracellular vesicles exhibit a mast cell signature, transfer KIT to stellate cells, and promote their activation","volume":"115","author":"Kim","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104724_b0260","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1002\/jex2.139","article-title":"Activation of the receptor KIT induces the secretion of exosome-like small extracellular vesicles","volume":"3","author":"Pfeiffer","year":"2024","journal-title":"J Extracell Biol"},{"key":"10.1016\/j.drudis.2026.104724_b0265","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1194\/jlr.R084640","article-title":"Extracellular vesicles and their content in bioactive lipid mediators: more than a sack of microRNA","volume":"59","author":"Boilard","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.drudis.2026.104724_b0270","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0304-4165(89)90157-8","article-title":"Synthesis of platelet-activating factor by human blood platelets and leucocytes. Evidence against selective utilization of cellular ether-linked phospholipids","volume":"993","author":"Sturk","year":"1989","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.drudis.2026.104724_b0275","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1006\/bbrc.1996.0166","article-title":"Platelet microparticles: a carrier of platelet-activating factor?","volume":"218","author":"Iwamoto","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2026.104724_b0280","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/iid3.224","article-title":"A case series: association of anaphylaxis with a significant decrease in platelet levels and possible secondary risk of thrombosis","volume":"6","author":"Peppers","year":"2018","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.drudis.2026.104724_b0285","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1073\/pnas.1502590112","article-title":"Emerging picture of the distinct traits and functions of microvesicles and exosomes","volume":"112","author":"Antonyak","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104724_b0290","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1073\/pnas.83.7.2204","article-title":"Leukotrienes C4 and D4 stimulate human endothelial cells to synthesize platelet-activating factor and bind neutrophils","volume":"83","author":"McIntyre","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104724_b0295","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jaci.2010.01.056","article-title":"Activation of human mast cells through the platelet-activating factor receptor","volume":"125","author":"Kajiwara","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0300","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1365-2567.2000.00972.x","article-title":"Demonstration that platelet-activating factor is capable of activating mast cells and inducing a chemotactic response","volume":"99","author":"Nilsson","year":"2000","journal-title":"Immunology"},{"key":"10.1016\/j.drudis.2026.104724_b0305","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.4049\/jimmunol.149.11.3682","article-title":"Human endothelial cells are target for platelet-activating factor. II. Platelet-activating factor induces platelet-activating factor synthesis in human umbilical vein endothelial cells","volume":"149","author":"Heller","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0310","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.4049\/jimmunol.139.7.2439","article-title":"Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures","volume":"139","author":"Bussolino","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0315","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.freeradbiomed.2012.05.031","article-title":"Determination of phospholipase activity of PAF acetylhydrolase","volume":"59","author":"Stafforini","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.drudis.2026.104724_b0320","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1016\/S0021-9258(18)61336-5","article-title":"Human plasma platelet-activating factor acetylhydrolase. Purification and properties","volume":"262","author":"Stafforini","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104724_b0325","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0021-9258(19)70115-X","article-title":"A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid)","volume":"256","author":"Blank","year":"1981","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104724_b0330","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1073\/pnas.86.7.2393","article-title":"Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma","volume":"86","author":"Stafforini","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104724_b0335","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1016\/S0021-9258(18)61335-3","article-title":"Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor","volume":"262","author":"Stafforini","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104724_b0340","doi-asserted-by":"crossref","first-page":"18772","DOI":"10.1074\/jbc.272.30.18772","article-title":"Studies of the nature of the binding by albumin of platelet-activating factor released from cells","volume":"272","author":"Ammit","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104724_b0345","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/jrf.0.1090309","article-title":"The role of albumin in the release of platelet-activating factor by mouse preimplantation embryos in vitro","volume":"109","author":"Ammit","year":"1997","journal-title":"J Reprod Fertil"},{"key":"10.1016\/j.drudis.2026.104724_b0350","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaci.2024.03.031","article-title":"Impaired high-density lipoprotein function and endothelial barrier stability in severe anaphylaxis","volume":"154","author":"Fernandez-Bravo","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0355","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/all.13176","article-title":"Serum levels of 9\u03b1,11\u03b2-PGF2 and apolipoprotein A1 achieve high predictive power as biomarkers of anaphylaxis","volume":"72","author":"Wittenberg","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.drudis.2026.104724_b0360","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.anai.2017.01.021","article-title":"Apolipoprotein B: a possible new biomarker for anaphylaxis","volume":"118","author":"Pettersson","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0365","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1476-5381.1992.tb14465.x","article-title":"Albumin inhibits platelet-activating factor (PAF)-induced responses in platelets and macrophages: implications for the biologically active form of PAF","volume":"107","author":"Grigoriadis","year":"1992","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2026.104724_b0370","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/clinchem\/41.10.1522","article-title":"Composition of interstitial fluid","volume":"41","author":"Fogh-Andersen","year":"1995","journal-title":"Clin Chem"},{"key":"10.1016\/j.drudis.2026.104724_b0375","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1161\/CIRCRESAHA.110.228742","article-title":"Circulating platelet-activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein-associated phospholipase A2\/ PAF acetylhydrolase","volume":"108","author":"Liu","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.drudis.2026.104724_b0380","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0024-3205(81)90031-X","article-title":"In vivo metabolism of a new class of biologically active phospholipids: 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a platelet activating-hypotensive phospholipid","volume":"29","author":"Blank","year":"1981","journal-title":"Life Sci"},{"key":"10.1016\/j.drudis.2026.104724_b0385","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0049-3848(86)90005-8","article-title":"The role of lipoproteins in the degradation of platelet-activating factor","volume":"44","author":"Ostermann","year":"1986","journal-title":"Thromb Res"},{"key":"10.1016\/j.drudis.2026.104724_b0390","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/MOL.0b013e3283630846","article-title":"Interstitial fluid lipoproteins","volume":"24","author":"Lundberg","year":"2013","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.drudis.2026.104724_b0395","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-2362.2006.01597.x","article-title":"Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system","volume":"36","author":"Parini","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.drudis.2026.104724_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104383","article-title":"Effectiveness of histamine receptor antagonists in the treatment of histamine-driven clinical symptoms: do we have a histamine or, better, an anti-histamine problem?","volume":"30","author":"Boehm","year":"2025","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104724_b0405","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0091-6749(05)80093-4","article-title":"In vivo effects of cetirizine on cutaneous reactivity and eosinophil migration induced by platelet-activating factor (PAF-acether) in man","volume":"86","author":"Fadel","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0410","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2340\/0001555572197200","article-title":"Effects of antihistamines on cutaneous reactions and influx of eosinophils after local injection of PAF, kallikrein, compound 48\/80 and histamine in patients with chronic urticaria and healthy subjects","volume":"72","author":"Juhlin","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.drudis.2026.104724_b0415","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2340\/0001555570151153","article-title":"Effect of cetirizine on cutaneous reactions to PAF, kallikrein and serum in patients with chronic urticaria","volume":"70","author":"Juhlin","year":"1990","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.drudis.2026.104724_b0420","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2465","article-title":"The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines","volume":"7","author":"Thurmond","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104724_b0425","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1365-2222.1993.tb00293.x","article-title":"Abnormalities in histamine pharmacodynamics in chronic urticaria","volume":"23","author":"Kanny","year":"1993","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.drudis.2026.104724_b0430","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/0091-6749(86)90377-5","article-title":"Discrimination between urticaria-prone and other allergic patients by intradermal skin testing with codeine","volume":"77","author":"Cohen","year":"1986","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0435","doi-asserted-by":"crossref","first-page":"C130","DOI":"10.1152\/ajpcell.1981.241.3.C130","article-title":"Contraction of Guinea pig ileal smooth muscle by acetyl glyceryl ether phosphorylcholine","volume":"241","author":"Findlay","year":"1981","journal-title":"Am J Physiol"},{"key":"10.1016\/j.drudis.2026.104724_b0440","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0014-2999(83)90532-0","article-title":"Acute microvascular effects of PAF-acether, as studied by intravital microscopy","volume":"96","author":"Bjoerk","year":"1983","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2026.104724_b0445","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(86)92489-X","article-title":"Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man","volume":"2","author":"Cuss","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2026.104724_b0450","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.4049\/jimmunol.145.11.3855","article-title":"The mechanism of mediator release from human basophils induced by platelet-activating factor","volume":"145","author":"Columbo","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0455","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0091-6749(95)70319-5","article-title":"Histamine release from human basophils induced by platelet activating factor: the role of extracellular calcium, interleukin-3, and granulocyte-macrophage colony-stimulating factor","volume":"95","author":"Columbo","year":"1995","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0460","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.4049\/jimmunol.131.5.2397","article-title":"The release of platelet-activating factor from human endothelial cells in culture","volume":"131","author":"Camussi","year":"1983","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0465","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/BF00517318","article-title":"Potentiation of leukotriene formation in pulmonary and vascular tissue","volume":"326","author":"Lefer","year":"1984","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.drudis.2026.104724_b0470","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1254\/jjp.54.217","article-title":"Platelet-activating factor (PAF)-induced rhinitis and involvement of PAF in allergic rhinitis in Guinea pigs","volume":"54","author":"Misawa","year":"1990","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.drudis.2026.104724_b0475","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1126\/science.7123233","article-title":"Nonimmunological production of leukotrienes induced by platelet-activating factor","volume":"218","author":"Voelkel","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104724_b0480","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0006-291X(84)80340-X","article-title":"Platelet-activating factor stimulation of peptidoleukotriene release: inhibition by vasoactive polypeptide","volume":"125","author":"Beaubien","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2026.104724_b0485","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/1523-1747.ep12514352","article-title":"In vivo studies of the pathogenesis of cold urticaria, cholinergic urticaria, and vibration-induced swelling","volume":"67","author":"Kaplan","year":"1976","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.drudis.2026.104724_b0490","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/bja\/65.6.833","article-title":"Massive histamine release in a patient with systemic mastocytosis","volume":"65","author":"Desborough","year":"1990","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.drudis.2026.104724_b0495","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1007\/s000110050279","article-title":"Histamine release during rapid vancomycin administration","volume":"47","author":"Renz","year":"1998","journal-title":"Inflamm Res"},{"key":"10.1016\/j.drudis.2026.104724_b0500","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1097\/00003246-199909000-00006","article-title":"Antihistamine prophylaxis permits rapid vancomycin infusion","volume":"27","author":"Renz","year":"1999","journal-title":"Crit Care Med"},{"key":"10.1016\/j.drudis.2026.104724_b0505","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00000542-198109000-00028","article-title":"Hemodynamics, plasma histamine, and catecholamine concentrations during an anaphylactoid reaction to morphine","volume":"55","author":"Fahmy","year":"1981","journal-title":"Anesthesiology"},{"key":"10.1016\/j.drudis.2026.104724_b0510","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1007\/BF01716946","article-title":"Definition and classification of the histamine-release response to drugs in anaesthesia and surgery: studies in the conscious human subject","volume":"60","author":"Lorenz","year":"1982","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.drudis.2026.104724_b0515","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1172\/JCI109936","article-title":"Physiologic manifestations of human anaphylaxis","volume":"66","author":"Smith","year":"1980","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2026.104724_b0520","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00000542-198202000-00003","article-title":"Histamine release during morphine and fentanyl anesthesia","volume":"56","author":"Rosow","year":"1982","journal-title":"Anesthesiology"},{"key":"10.1016\/j.drudis.2026.104724_b0525","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00000542-198109000-00019","article-title":"The use of H1 and H2 histamine antagonists with morphine anesthesia: a double-blind study","volume":"55","author":"Philbin","year":"1981","journal-title":"Anesthesiology"},{"key":"10.1016\/j.drudis.2026.104724_b0530","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.eclinm.2018.07.002","article-title":"Immediate hypersensitivity to contrast agents: the French 5-year CIRTACI study","volume":"1","author":"Clement","year":"2018","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.drudis.2026.104724_b0535","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/ALN.0000000000001600","article-title":"In vivo cysteinyl leukotriene release in allergic and nonallergic immediate hypersensitivity reactions during anesthesia","volume":"126","author":"Laroche","year":"2017","journal-title":"Anesthesiology"},{"key":"10.1016\/j.drudis.2026.104724_b0540","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0091-6749(82)80005-5","article-title":"Effects of infused histamine: correlation of plasma histamine levels and symptoms","volume":"69","author":"Kaliner","year":"1982","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.drudis.2026.104724_b0545","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/BF01716957","article-title":"Effects of histamine on the circulatory system","volume":"60","author":"Owen","year":"1982","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.drudis.2026.104724_b0550","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1177\/009127002401102713","article-title":"Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2","volume":"42","author":"Middleton","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2026.104724_b0555","doi-asserted-by":"crossref","unstructured":"Weiss-Tessbach M et al. Effect of intramuscular Adrenaline on histamine-induced hypotension: a randomised placebo-controlled pilot trial. Allergy. Published online March 2, 2026. https:\/\/doi.org\/10.1111\/all.70277.","DOI":"10.1111\/all.70277"},{"key":"10.1016\/j.drudis.2026.104724_b0560","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF01980899","article-title":"Plasma histamine and clinical tolerance to infused histamine in normal, atopic and urticarial subjects","volume":"32","author":"Pollock","year":"1991","journal-title":"Agents Actions"},{"key":"10.1016\/j.drudis.2026.104724_b0565","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1172\/JCI101764","article-title":"The action of histamine on the respiratory tract in normal and asthmatic subjects","volume":"25","author":"Curry","year":"1946","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2026.104724_b0570","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.68542","article-title":"Heparin-binding motif mutations of human diamine oxidase allow the development of a first-in-class histamine-degrading biopharmaceutical","volume":"10","author":"Gludovacz","year":"2021","journal-title":"Elife"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:42:13Z","timestamp":1789504933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626001297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":114,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1359644626001297"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104724","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Critical evaluation of the key mediators causing life-threatening symptoms during human anaphylaxis","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104724","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104724"}}